Tvardi Therapeutics (TVRD)

• Market cap: $43.7M
• 1 day: -2.51%
• 5 days: -9.69%
• 1 month: -88.04%
• 3 months: -81.86%
• 6 months: -81.32%
• Year to date: -71.02%
• 1 year: -55.19%
• 5 years: -99.02%
• 10 years: -99.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.